...
首页> 外文期刊>European review for medical and pharmacological sciences. >HMGN5 expression in bladder cancer tissue and its role on prognosis
【24h】

HMGN5 expression in bladder cancer tissue and its role on prognosis

机译:HMGN5在膀胱癌组织中的表达及其在预后中的作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: High mobility group protein N5 subtype (HMGN5) is overexpressed in bladder cancer tissue, while its specific mechanism in bladder cancer oncogenesis has not been fully elucidated. This study intends to investigate the impact of HMGN5 on clinical staging and prognosis of bladder cancer. PATIENTS AND METHODS: A total of 26 cases of patients with bladder transitional cell carcinoma (BTCC) received transurethral resection (TUR-BT) in our hospital between March 2015 and February 2016. Para-carcinoma tissue at 5 cm away from cancer tissue was selected as normal control. The expressions of HMGN5 mRNA and protein in different clinical stages were tested by Real-time PCR and Western blot. The relationship between HMGN5 expression and clinical stage along with prognosis was analyzed. RESULTS: HMGN5 mRNA was significantly elevated in BTCC tissue compared with that in para-carcinoma tissue (p < 0.05). HMGN5 mRNA level was gradually upregulated following BTCC upstage according to UICC-TNM stage and WHO stage. The level of HMGN5 protein showed similar changes with mRNA. Follow-up results demonstrated that patients with high HMGN5 level have more tendency of occurrence. CONCLUSIONS: HMGN5 protein level has an important influence on BTCC clinicopathological staging and prognosis. This investigation provides theoretical basis the future therapy of bladder cancer.
机译:目的:高迁移率族蛋白N5亚型(HMGN5)在膀胱癌组织中过度表达,但其在膀胱癌发生中的具体机制尚未完全阐明。本研究旨在探讨HMGN5对膀胱癌临床分期和预后的影响。患者与方法:2015年3月至2016年2月间,我院共对26例膀胱移行细胞癌(BTCC)患者进行了经尿道切除术(TUR-BT)。选择了距癌组织5 cm的癌旁组织作为正常控制。实时荧光定量PCR和Western blot检测HMGN5 mRNA和蛋白在不同临床阶段的表达。分析了HMGN5表达与临床分期及预后的关系。结果:与癌旁组织相比,BTCC组织中HMGN5 mRNA显着升高(p <0.05)。根据UICC-TNM分期和WHO分期,BTCC后,HMGN5 mRNA水平逐渐升高。 HMGN5蛋白的水平显示与mRNA相似的变化。随访结果表明,高HMGN5水平的患者有更多的发生趋势。结论:HMGN5蛋白水平对BTCC临床病理分期和预后有重要影响。该研究为膀胱癌的未来治疗提供了理论依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号